These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27220765)

  • 21. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Qian XL; Wen HY; Yang YL; Gu F; Guo XJ; Liu FF; Zhang L; Zhang XM; Fu L
    Breast Cancer Res Treat; 2016 Aug; 159(1):31-9. PubMed ID: 27455837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines.
    Yang L; Chen M; Pu T; Wu S; Wei B; Yang J; Bu H; Zhang Z
    J Clin Pathol; 2020 May; 73(5):283-290. PubMed ID: 31732618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.
    Kong H; Bai Q; Li A; Zhou X; Yang W
    Diagn Pathol; 2022 Jan; 17(1):5. PubMed ID: 34996485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
    Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
    Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
    Polónia A; Leitão D; Schmitt F
    Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
    Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
    J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
    Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
    Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
    Ying JM; Liu XY; Guo L; Xie YQ; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
    Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
    Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M; Caramelo AS; Eloy C; Polónia A
    Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for Her2 immunohistochemistry.
    Onguru O; Zhang PJ
    Pathol Res Pract; 2016 May; 212(5):381-4. PubMed ID: 26872536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.
    Franchet C; Filleron T; Cayre A; Mounié E; Penault-Llorca F; Jacquemier J; Macgrogan G; Arnould L; Lacroix-Triki M
    Histopathology; 2014 Jan; 64(2):274-83. PubMed ID: 24117939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X; Shi J; Li Z; Feng A; Ye Q
    Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Image cytometric HER2 in gastric carcinoma: is a new algorithm needed?
    Ormenisan C; Wang J; Lawson D; Cohen C
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):414-9. PubMed ID: 23197004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.